HAylation of Tranexamic acid microneedling in melasma: A controlled comparative split-face trial
Background Melasma is a common, challenging hyperpigmentation causing a significant negative impact on quality of life. Tranexamic acid (TXA) showed optimistic results, however, optimization of administration protocol is required to enhance and sustain therapeutic outcomes. Objective This trial evaluated the additive effect of hyaluronic acid (HA) when combined with TXA microneedling in melasma. Methods This split-face trial included 27 patients with bilateral melasma. Disease severity was assessed by hemi-modified Melasma Area and Severity Index (hmMASI) and dermoscopic examination. The right side of the face received TXA (100mg/ml) via microneedling, while the left side received HA 3.5% co-administered with TXA microneedling. Sessions were held once every two weeks for six sessions. Results Both treatment protocols showed significant reduction in hmMASI and dermoscopy (P<0.001 and P=0.01 respectively). The HA-TXA treated side demonstrated significantly higher improvement than TXA alone (P=0.003) with significantly higher percentage of excellent responders 66.7% versus 18.5% respectively (P<0.001). The TXA treated side showed resurgence of melasma (P=0.005), while the therapeutic response was sustained on the HA-TXA treated side (P=1). Additionally, the vascularity improvement was significantly higher on the hyaluronic-tranexamic acid treated side (P=0.012). Conclusions The co-administration of hyaluronic acid with tranexamic acid microneedling in melasma patients increases treatment efficacy, sustains its effects and reduces downtime and side effects.
Authors
- Hagar O. Nofal (ORCID: https://orcid.org/0000-0003-3781-6794)
- Nourhan Anis (ORCID: https://orcid.org/0000-0002-9965-704X)
- Enayat Mohamed Atwa
- Omnia Tarabya
Institutions
- Zagazig University (EG)
- American University in Cairo (EG)
Publication Details
- Journal
- Clinical and Experimental Dermatology
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1093/ced/llag485
- Primary Topic
- Dermatologic Treatments and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00